TAS 05567
Alternative Names: TAS-05567; TAS-5567Latest Information Update: 28 Dec 2021
Price :
$50 *
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Idiopathic thrombocytopenic purpura; Rheumatoid arthritis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Idiopathic thrombocytopenic purpura in Japan (PO)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Japan (PO)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in Japan (PO)